Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2000

01-04-2000 | Review

Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development

Author: Jacqueline Bromberg

Published in: Breast Cancer Research | Issue 2/2000

Login to get access

Abstract

STAT transcription factors were discovered 10 years ago as mediators of interferon-induced gene expression. They now form an important group, comprising seven members, that are activated by virtually every cytokine and growth factor. Their critical role in development and normal cell signaling has been largely determined through the analysis of transgenic mice lacking individual STAT genes. In addition, cell culture work has further delineated their importance in cellular transformation, apoptosis, differentiation and growth control. This review discusses the specific phenotypes of STAT-deficient animals with a focus on STAT5 and STAT3, as these two STAT molecules are required for normal breast development and involution, respectively, and may play an important role in breast carcinogenesis.
Literature
1.
Darnell JE: STATs and gene regulation. Science. 1997, 277: 1630-1635. 10.1126/science.277.5332.1630.CrossRefPubMed
2.
Stark GR, Kerrr IM, Williams BR, et al: How cells respond to interferons. Annu Rev Biochem. 1998, 67: 227-264. 10.1146/annurev.biochem.67.1.227.CrossRefPubMed
3.
Chen X, Vinkemeier U, Zhao Y, et al: Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell. 1998, 93: 827-839. 10.1016/S0092-8674(00)81443-9.CrossRefPubMed
4.
Haspel RL, Salditt-Georgieff M, Darnell JE: The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends on a protein tyrosine phosphatase. EMBO J. 1996, 15: 6262-6268.PubMedPubMedCentral
5.
Haspel RL, Darnell JE: A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. Proc Natl Acad Sci USA. 1999, 96: 10188-10193. 10.1073/pnas.96.18.10188.CrossRefPubMedPubMedCentral
6.
Kaplan MH, Schindler U, Smiley ST, et al: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996, 4: 313-319.CrossRefPubMed
7.
Thierfelder WE, van Deursen JM, Yamamoto K, et al: Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996, 382: 171-174. 10.1038/382171a0.CrossRefPubMed
8.
Takeda K, Tanaka T, Shi W, et al: Essential role of Stat6 in IL-4 signalling. Nature. 1996, 380: 627-630. 10.1038/380627a0.CrossRefPubMed
9.
Shimoda K, Deursen JV, Sangster MY, et al: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 1996, 380: 630-633. 10.1038/380630a0.CrossRefPubMed
10.
Meraz MA, White JM, Sheehan KCF, et al: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996, 84: 431-442. 10.1016/S0092-8674(00)81288-X.CrossRefPubMed
11.
Durbin JE, Hackenmiller R, Simon MC, et al: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996, 84: 443-450. 10.1016/S0092-8674(00)81289-1.CrossRefPubMed
12.
Kaplan DH, Shankaran V, Dighe AS, et al: Demonstration of an interferon gamma-dependent tumor surveillance system in immuno-competent mice. Proc Natl Acad Sci USA. 1998, 95: 7556-7561. 10.1073/pnas.95.13.7556.CrossRefPubMedPubMedCentral
13.
Bromberg JF, Horvath CM, Wen Z, et al: Transcriptionally active Stat1 is required for the antiproliferative effects of both IFN-α and IFN-γ. Proc Natl Acad Sci USA. 1996, 93: 7673-7678. 10.1073/pnas.93.15.7673.CrossRefPubMedPubMedCentral
14.
Kumar A, Commane M, Flickinger TW, et al: Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science. 1997, 278: 1630-1632. 10.1126/science.278.5343.1630.CrossRefPubMed
15.
Shuai K, Halpern J, ten Hoeve J, et al: Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996, 13: 247-254.PubMed
16.
Migone TS, Lin JX, Cereseto A, et al: Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995, 269: 79-81.CrossRefPubMed
17.
Teglund S, McKay C, Schuetz E, et al: Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998, 93: 841-850. 10.1016/S0092-8674(00)81444-0.CrossRefPubMed
18.
Socolovsky M, Fallon AE, Wang S, et al: Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999, 98: 181-191.CrossRefPubMed
19.
Onishi M, Nosaka T, Misawa K, et al: Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998, 18: 3871-3879.CrossRefPubMedPubMedCentral
20.
Nosaka T, Kawashima T, Misawa K, et al: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999, 18: 4754-4765. 10.1093/emboj/18.17.4754.CrossRefPubMedPubMedCentral
21.
Moriggl R, Topham DJ, Teglund S, et al: Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999, 10: 249-259.CrossRefPubMed
22.
Nieborowska-Skorska M, Wasik M, Slupianek A, et al: Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL is required for leukemogenesis. J Exp Med. 1999, 189: 1229-1242. 10.1084/jem.189.8.1229.CrossRefPubMedPubMedCentral
23.
Topper YJ, Freeman CS: Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev. 1980, 60: 1049-1056.PubMed
24.
Vonderhaar BK: Local effects of EGF, alpha-TGF, and EGF-like growth factors on lobuloalveolar development of the mouse mammary gland in vivo. J Cell Physiol. 1987, 132: 581-584.CrossRefPubMed
25.
Liu X, Robinson GW, Wagner K-U, et al: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11: 179-186.CrossRefPubMed
26.
Liu X, Robinson GW, Hennighausen L: Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol. 1996, 10: 1496-1506. 10.1210/me.10.12.1496.PubMed
27.
Udy GB, Towers RP, Snell RG, et al: Requirement of Stat5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA. 1997, 94: 7239-7244. 10.1073/pnas.94.14.7239.CrossRefPubMedPubMedCentral
28.
Sebastian J, Richards RG, Walker MP, et al: Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ. 1998, 9: 777-785.PubMed
29.
Olayioye MA, Beuvink I, Horsch K, et al: ErbB receptor-induced activation of stat transcription factors is mediated by src tyrosine kinases. J Biol Chem. 1999, 274: 17209-17218. 10.1074/jbc.274.24.17209.CrossRefPubMed
30.
Stoecklin E, Wissler M, Schaetzle D, et al: Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol. 1999, 69: 195-204. 10.1016/S0960-0760(99)00052-7.CrossRefPubMed
31.
Takeda K, Noguchi K, Shi W, et al: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA. 1997, 94: 3801-3804. 10.1073/pnas.94.8.3801.CrossRefPubMedPubMedCentral
32.
Garcia R, Jove R: Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci. 1998, 5: 79-85. 10.1159/000025316.CrossRefPubMed
33.
Weber-Nordt RM, Egen C, Wehinger J, et al: Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood. 1996, 88: 809-816.PubMed
34.
Bromberg JF, Horvath CM, Besser D, et al: Stat3 activation is required for cellular transformation by v-src . Mol Cell Biol. 1998, 5: 2553-2558.CrossRef
35.
36.
Turkson J, Bowman T, Garcia R, et al: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998, 18: 2545-2552.CrossRefPubMedPubMedCentral
37.
Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999, 10: 105-115.CrossRefPubMed
38.
Grandis JR, Drenning SD, Chakraborty A, et al: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 1998, 102: 1385-1392.CrossRefPubMedPubMedCentral
39.
Bonni A, Sun Y, Nadal-Vicens M, et al: Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science. 1997, 278: 477-483. 10.1126/science.278.5337.477.CrossRefPubMed
40.
Ihara S, Nakajima K, Fukada T, et al: Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6. EMBO J. 1997, 16: 5345-5352. 10.1093/emboj/16.17.5345.CrossRefPubMedPubMedCentral
41.
Nielsen M, Kaestel CG, Eriksen KW, et al: Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999, 13: 735-738. 10.1038/sj/leu/2401415.CrossRefPubMed
42.
Fukada T, Ohtani T, Yoshida Y, et al: STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 1998, 17: 6670-6677. 10.1093/emboj/17.22.6670.CrossRefPubMedPubMedCentral
43.
Kuhn R, Schwenk F, Aguet M, et al: Inducible gene targeting in mice. Science. 1995, 269: 1427-1429.CrossRefPubMed
44.
Takeda K, Kaisho T, Yoshida N, et al: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell- specific Stat3-deficient mice. J Immunol. 1998, 161: 4652-4660.PubMed
45.
Sano S, Itami S, Takeda K, et al: Keratinocyte-specific ablation of stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999, 18: 4657-4668. 10.1093/emboj/18.17.4657.CrossRefPubMedPubMedCentral
46.
Chapman RS, Lourenco PC, Tonner E, et al: Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of STAT3. Genes Dev. 1999, 13: 2604-2616. 10.1101/gad.13.19.2604.CrossRefPubMedPubMedCentral
47.
Minami M, Inoue M, Wei S, et al: STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci USA. 1996, 93: 3963-3966. 10.1073/pnas.93.9.3963.CrossRefPubMedPubMedCentral
48.
Nakajima K, Yamanaka Y, Nakae K, et al: A centrol role of Stat3 in IL6 induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996, 15: 3651-3658.PubMedPubMedCentral
49.
O'Farrell AM, Liu Y, Moore KW, et al: IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998, 17: 1006-1018. 10.1093/emboj/17.4.1006.CrossRefPubMedPubMedCentral
50.
Kiuchi N, Nakajima K, Ichiba M, et al: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999, 189: 63-73. 10.1084/jem.189.1.63.CrossRefPubMedPubMedCentral
51.
Cole MD, McMahon SB: The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 1999, 18: 2916-2924. 10.1038/sj.onc.1202748.CrossRefPubMed
52.
Watson CJ, Miller WR: Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer. 1995, 71: 840-844.CrossRefPubMedPubMedCentral
53.
Garcia R, Yu CL, Hudnall A, et al: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997, 8: 1267-1276.PubMed
54.
Naka T, Narazaki M, Hirata M, et al: Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997, 387: 924-929. 10.1038/43219.CrossRefPubMed
55.
Chung CD, Liao J, Liu B, et al: Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997, 278: 1803-1805. 10.1126/science.278.5344.1803.CrossRefPubMed
56.
Matsumura I, Kitamura T, Wakao H, et al: Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 1999, 18: 1367-1377. 10.1093/emboj/18.5.1367.CrossRefPubMedPubMedCentral
57.
Wang TC, Cardiff RD, Zukerberg L, et al: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994, 369: 669-671. 10.1038/369669a0.CrossRefPubMed
58.
Weinstat-Saslow D, Merino MJ, Manrow RE, et al: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med. 1995, 1: 1257-1260.CrossRefPubMed
59.
Norton L, Rosen PP, Rosen N: Refining the origins of breast cancer. Nature Med. 1995, 1: 1250-1251.CrossRefPubMed
60.
Gillett CE, Lee AH, Millis RR, et al: Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol. 1998, 184: 396-400. 10.1002/(SICI)1096-9896(199804)184:4<396::AID-PATH1259>3.0.CO;2-G.CrossRefPubMed
61.
Alle KM, Henshall SM, Field AS, et al: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res. 1998, 4: 847-854.PubMed
62.
Berns EM, Klijn JG, van Putten WL, et al: c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992, 52: 1107-1113.PubMed
63.
Nass SJ, Dickson RB: Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc . Clin Cancer Res. 1998, 4: 1813-1822.PubMed
64.
Guerin M, Barrois M, Terrier MJ, et al: Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988, 3: 21-31.PubMed
65.
Nakopoulou L, Michalopoulou A, Giannopoulou I, et al: bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology. 1999, 34: 310-319. 10.1046/j.1365-2559.1999.00627.x.CrossRefPubMed
66.
Liu JR, Fletcher B, Page C, et al: Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol. 1998, 70: 398-403. 10.1006/gyno.1998.5125.CrossRefPubMed
67.
Vakkala M, Lahteenmaki K, Raunio H, et al: Apoptosis during breast carcinoma progression. Clin Cancer Res. 1999, 5: 319-324.PubMed
Metadata
Title
Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development
Author
Jacqueline Bromberg
Publication date
01-04-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr38

Other articles of this Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue

Review

Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models

Commentary

Founder populations and their uses for breast cancer genetics

Review

Transforming growth factor-β and breast cancer: Cell cycle arrest by transforming growth factor-β and its disruption in cancer

Commentary

Caretaker Brca1: keeping the genome in the straight and narrow

Meeting report

22nd Annual San Antonio Breast Cancer Symposium, 8-11 December 1999, San Antonio, Texas, USA

Review

Transforming growth factor-β and breast cancer: Mammary gland development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits